Breaking News Instant updates and real-time market news.

ALDX

Aldeyra

$10.08

-0.19 (-1.85%)

, EOLS

Evolus

$14.59

-0.13 (-0.88%)

04:55
11/14/18
11/14
04:55
11/14/18
04:55

Stifel to hold a conference

2018 Healthcare Conference will be held in New York on November 13-14.

ALDX

Aldeyra

$10.08

-0.19 (-1.85%)

EOLS

Evolus

$14.59

-0.13 (-0.88%)

LXRX

Lexicon

$8.41

0.06 (0.72%)

KURA

Kura Oncology

$11.58

0.11 (0.96%)

URGN

UroGen Pharma

$46.33

0.83 (1.82%)

MNTA

Momenta

$12.79

-0.36 (-2.74%)

ASRT

Assertio Therapeutics

$5.38

(0.00%)

ATEC

Alphatec

$2.85

-0.13 (-4.36%)

ITRM

Iterum Therapeutics

$5.92

0.21 (3.68%)

CUTR

Cutera

$20.32

0.24 (1.20%)

IBIO

iBio

$0.78

0.045 (6.16%)

HRC

Hill-Rom

$93.52

-0.9 (-0.95%)

TRXC

TransEnterix

$2.88

-0.2 (-6.49%)

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 27

    Nov

  • 27

    Nov

  • 01

    Dec

  • 02

    Feb

  • 22

    Mar

ALDX Aldeyra
$10.08

-0.19 (-1.85%)

09/26/18
ADAM
09/26/18
NO CHANGE
Target $35
ADAM
Buy
Aldeyra price target raised to $35 from $27 at Canaccord
Canaccord analyst John Newman raised his price target on Aldeyra shares to $35 from $27 after the company's Phase 2b trial of topical ocular reproxalap in patients with dry eye disease achieved statistically significant improvement against vehicle for all imputation techniques, which he called a "major positive." The very rapid onset of action is differentiating, said the analyst, who expects positive Phase 3 dry eye data given the Phase 2b results. He maintains a Buy rating on Aldeyra shares.
09/26/18
STFL
09/26/18
NO CHANGE
Target $36
STFL
Buy
Aldeyra price target raised to $36 from $16 at Stifel
Stifel analyst Adam Walsh believe Aldeyra's "strong" reproxalap trial results in dry eye disease position the company as "a legitimate player in this blockbuster market." Safety was clean, tolerability was in-line with approved treatments and the early onset of action makes reproxalap look highly differentiated, Walsh added. While Aldeyra likely needs to raise capital to run its two planned dry eye disease Phase 3 trials, Walsh believes the current valuation appears attractive, he tells investors. The analyst raised his price target on Aldeyra shares to $36 from $16 and keeps a Buy rating on the stock.
09/13/18
09/13/18
INITIATION
Target $21

Buy
Janney Montgomery Scott starts Aldeyra with a Buy, $21 fair value estimate
As previously reported, Janney Montgomery Scott initiated Aldeyra with a Buy rating, with analyst Esther Hong stating that she is positive on all four of its late-stage programs based on safety and efficacy data to date. She sees data from the programs for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome providing significant upside over the next 12 months to shares of Aldeyra, on which Hong set a $21 fair value estimate.
09/26/18
CANT
09/26/18
NO CHANGE
Target $30
CANT
Aldeyra price target raised to $30 from $23 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemor Piros raised Overweight rated Aldeyra's price target to $30 from $23 following positive Phase 2b dry eye data with reproxalap. The analyst believes the results signal the potential for strategic partnership and M&A activity.
EOLS Evolus
$14.59

-0.13 (-0.88%)

06/13/18
CANT
06/13/18
NO CHANGE
Target $35
CANT
Overweight
Evolus price target raised to $35 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target for Evolus to $35 citing improved visibility for the peak sales potential of DWP-450. Although Evolus is not providing the details of its Complete Response Letter, the company said that over half of the questions listed in the CRL have been resolved, Chen tells investors in a research note. The analyst continues to see a "smooth" path to approval and keeps an Overweight rating on Evolus shares.
10/11/18
MZHO
10/11/18
NO CHANGE
Target $27
MZHO
Buy
Evolus pulled back on misinterpretation of article, says Mizuho
Mizuho analyst Irina Koffler believes investors yesterday may have overreacted to a Korea Herald article dated October 4. The article, which the analyst believes is being taken out of content, said Evolus partner Daewoong had terminated its clinical trial application for its botulinum toxin drug Nabota on plans to refile with another production site. Koffler confirmed with Evolus management that Daewoong is going to make Nabota at the plant that recently passed FDA inspection for DWP-450. The article is being misinterpreted to mean that there is some manufacturing risk to DWP-450 in the U.S., which may be incorrect, Koffler told investors yesterday in a research note. She reiterates a Buy rating on Evolus with a $27 price target. The stock closed yesterday down 10.5%, or $1.72, to $14.71.
08/02/18
JMPS
08/02/18
NO CHANGE
Target $35
JMPS
Outperform
Evolus price target raised to $35 from $30 at JMP Securities
JMP Securities analyst Donald Ellis raised his price target for Evolus (EOLS) to $35 and reiterates an Outperform rating on the shares following the company's Q2 results. The analyst now assumes that DWP-450 will price at a 10% price discount relative to Allergan's (AGN) Botox versus 20% previously. He notes that DWP-450 will not go to market as simply a "generic" Botox, but rather a branded player with a "with a smart go-to-market strategy." The Evolus management team is "carefully and thoughtfully building an aesthetic only major player in the U.S. cosmetic market," Ellis tells investors in a research note.
09/18/18
CANT
09/18/18
NO CHANGE
Target $35
CANT
Overweight
Evolus selloff yesterday not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen sees no fundamental reason for the 12% pullback yesterday in shares of Evolus (EOLS). The stock weakness was partly attributed to the "upbeat and well-attended" investor day held by competitor Allergan (AGN) last Friday, Chen tells investors in a research note. The analyst points out that shares of Revance (RVNC), which also competes with Allergan in the botulinum toxin space, dropped yesterday as well. Chen believes Allergan's investor day renewed concerns that the company is and will remain the leading botulinum toxin/aesthetics player in the space. However, this is nothing new and is already priced into Evolus' valuation, Chen contends. The analyst continues to expect the company's launch of DWP-450 in spring 2019 to exceed "modest expectations." She keeps an Overweight rating on the shares with a $35 price target.
LXRX Lexicon
$8.41

0.06 (0.72%)

02/23/18
NEED
02/23/18
DOWNGRADE
NEED
Hold
Lexicon downgraded to Hold at Needham
As reported earlier, Needham analyst Alan Carr downgraded Lexicon Pharma to Hold from Buy after the company's U.S. Xermelo sales came in below expectations. Carr cites the ongoing challenges that include "low number of patient starts and a large number of Medicare patients receiving free drug under a company assistance program". While the company believes that patient starts are rebounding, the analyst contends that Xermelo launch trajectory implies a more modest peak in sales.
02/14/18
02/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to In Line from Outperform at Evercore ISI with analyst Robert Ottenstein saying that while the company's dividend increase is "important and positive," he no longer expects the company to outperform in the beverage sector amid an "array of issues" at North America Beverage segment limiting upside performance. 2. Spark Therapeutics (ONCE) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying he remains optimistic about the long-term outlook for the company, but notes the shares are now within 10% of his price target following the recent rally. 3. Chimerix (CMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying with base-case timing for the AdAPT data well over a year away, the shares will underperform over the near term. 4. Avis Budget (CAR) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying he believes transitory benefits from Hurricane recovery demand are waning, and headwinds from reduced residual values, higher interest rates, continued competition, and increased SG&A expenses will pressure Avis' earnings outlook. 5. Lexicon (LXRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying the Xermelo launch remains slow, and consensus estimates of $55M and $99M for 2018 and 2019 are too high. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/22/18
WEDB
05/22/18
NO CHANGE
Target $42
WEDB
Outperform
Lexicon price target raised to $42 from $40 at Wedbush
02/23/18
NEED
02/23/18
DOWNGRADE
NEED
Hold
Lexicon downgraded to Hold from Buy at Needham
KURA Kura Oncology
$11.58

0.11 (0.96%)

10/22/18
HCWC
10/22/18
NO CHANGE
Target $31
HCWC
Buy
H.C. Wainwright 'very encouraged' by Kura data, reiterates $31 price target
Kura Oncology this morning announced a positive outcome on its lead therapeutic candidate, tipifarnib, in Phase 2 clinical trial addressing the role of the drug in HRAS positive squamous cell carcinomas, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The analyst believes the data show the validation of the therapeutic efficacy of tipifarnib and better clinical efficacy than current standards of care. "Although the market potential could seem minor, we are very encouraged tipifarnib represents a suitable and the first targeted therapy for HRAS high mutant HNSCC, and should open doors to initial tumor indications," writes Pantginis. He reiterates a Buy rating on Kura Oncology with a $31 price target.
11/09/18
PIPR
11/09/18
INITIATION
Target $25
PIPR
Overweight
Kura Oncology initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren started Kura Oncology with an Overweight rating and $25 price target. While the shares have pulled back after the response rate in the Phase II trial of tipifarnib experienced a moderate decline, the drug still demonstrated a 50% response rate in head and neck squamous cell carcinoma patients with HRAS mutations, Van Buren tells investors in a research note. He believes these results are clinically meaningful and that tipifarnib "appears to be a promising treatment option for these patients." Kura's current valuation is "very reasonable" for a de-risked potential $500M-plus cancer drug, says the analyst.
11/09/18
11/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. RH (RH) initiated with an Overweight at JPMorgan. 2. Ascendis Pharma (ASND) initiated with an Outperform at Credit Suisse. 3. Kura Oncology (KURA) initiated with an Overweight at Piper Jaffray. 4. Equitrans Midstream (ETRN) initiated with a Buy at Jefferies. 5. Instructure (INST) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
08/01/18
HCWC
08/01/18
INITIATION
Target $31
HCWC
Buy
Kura Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Kura Oncology with a Buy rating and $31 price target. The shares currently do not reflect the overall opportunity for tipifarnib, which is about to enter a pivotal program in head and neck squamous cell carcinoma patients as well as several other indications, which could lead to a broad label for the drug, Pantginis tells investors in a research note.
URGN UroGen Pharma
$46.33

0.83 (1.82%)

04/04/18
RAJA
04/04/18
UPGRADE
RAJA
Outperform
UroGen Pharma upgraded to Outperform from Market Perform at Raymond James
09/13/18
STFL
09/13/18
INITIATION
STFL
Buy
UroGen Pharma initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated UroGen Pharma with a Buy rating and a $70 price target. Archila noted that the company has a late-stage asset that is largely de-risked with an attractive, niche commercial opportunity, and also has an emerging pipeline and validated platform. The analyst added that investors are under appreciating the opportunity for MitoGel in UTUC, and believes the stock has room to run.
11/08/18
JEFF
11/08/18
INITIATION
Target $77
JEFF
Buy
UroGen Pharma assumed with a Buy at Jefferies
Jefferies analyst Chris Howerton assumed coverage of UroGen Pharma with a Buy rating and $77 price target. The company's lead assets have shown "strong" clinical data, and have potential to become standard of care in their respective indications, says the analyst.
04/06/18
OPCO
04/06/18
NO CHANGE
Target $75
OPCO
Outperform
UroGen Pharma price target raised to $75 from $62 at Oppenheimer
Oppenheimer analyst Derek Archila raised his price target on UroGen Pharma to $75 from $62. Archila told investors in a research note that he is increasing his probability of success for MitoGel in upper tract urothelial carcinoma, or UTUC, based on "impressive" interim results from its OLYMPUS Phase 3 study, in which the complete response rate was better than seen in the compassionate use study. Archila reiterated an Outperform rating on UroGen shares.
MNTA Momenta
$12.79

-0.36 (-2.74%)

11/05/18
PIPR
11/05/18
INITIATION
Target $35
PIPR
Overweight
Momenta initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill started Momenta Pharmaceuticals with an Overweight rating and $35 price target. The company offers a "rare" biotech investment opportunity as its stock is "super cheap" and its anti-FcRn therapies could be game changing for treating auto-immune diseases, Brill tells investors in a research note. Momenta's proprietary pipeline has "major blockbuster potential and is underappreciated by investors," says the analyst.
10/11/18
PIPR
10/11/18
NO CHANGE
PIPR
Overweight
Piper says Momenta update underscores safer profile of Argenx's efgartigimod
Piper Jaffray analyst Edward Tenthoff noted that at Momenta's (MNTA) R&D Day the company shared additional safety data for anti-FcRn antibody M281, disclosing that three subjects in the multiple ascending dose cohort of the Phase 1 study experienced CK elevation and terminated dosing. Also, a 25-30% reduction in serum albumin was reported across single and multiple dosing cohorts, said Tenthoff, who added that neither of these events were observed in Argenx's (ARGX) animal or healthy volunteer studies for efgartigimod. The analyst, who believes efgartigimod produces similar activity without compromising safety and sees the company as about two years ahead of Momenta, keeps an Overweight rating and $154 price target on Argenx shares.
11/07/18
STFL
11/07/18
NO CHANGE
STFL
Stifel still bullish on Momenta despite overhang, controversies
Stifel analyst Derek Archila maintained a Buy rating on Momenta and lowered his price target on shares to $39 from $40 after the company's Q3 earnings report. Archila said the earnings were a "non-event" and that he remains bullish in his long-term thesis on Momenta as he is optimistic about the company's M281 program, despite a near-term financial overhang and controversy surrounding M281's safety profile -- which the analyst has previously stated he is not overly concerned with.
09/13/18
STFL
09/13/18
INITIATION
Target $40
STFL
Buy
Momenta assumed with a Buy at Stifel
Stifel analyst Derek Archila assumed Momenta with a Buy rating and a price target of $40, saying the stock offers an investment in an "exciting biotech company that has a pipeline with demonstrated proof-of-mechanism". The analyst expects sentiment on Momenta to shift as it "completes its strategic review, ideally sheds costs/potentially monetizes its legacy businesses, and narrows its focus on its proprietary pipeline M281 and M254.
ASRT Assertio Therapeutics
$5.38

(0.00%)

08/29/18
JANY
08/29/18
DOWNGRADE
JANY
Neutral
Assertio Therapeutics downgraded to Neutral from Buy at Janney Montgomery Scott
ATEC Alphatec
$2.85

-0.13 (-4.36%)

ITRM Iterum Therapeutics
$5.92

0.21 (3.68%)

06/19/18
RBCM
06/19/18
INITIATION
Target $24
RBCM
Outperform
Iterum Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Gregory Renza initiated Iterum Therapeutics with an Outperform rating and a price target of $24. The analyst cites the company's sulopenem treatment becoming a viable therapeutic option for resistance pathogens in the "high-opportunity" UTI market. The analyst adds that a "clear pivotal path" for the antibiotic gives the stock price the appreciation potential.
06/19/18
NEED
06/19/18
INITIATION
Target $20
NEED
Buy
Iterum Therapeutics initiated with a Buy at Needham
Needham analyst Alan Carr initiated Iterum Therapeutics with a Buy rating and a price target of $20, saying the company's sulopenem antibiotic addresses the unmet need for treatment of urinary tract infections. The analyst anticipates a phase 3 initiation for sulopenem in the second half of this year and a launch by the first quarter of 2021, estimating peak U.S. sales reaching $700M by 2033.
06/19/18
06/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ollie's Bargain Outlet (OLLI) initiated with a Hold at Loop Capital. 2. B&G Foods (BGS) assumed with a Neutral at Piper Jaffray. 3. Iterum Therapeutics (ITRM) initiated with an Outperform at RBC Capital and Leerink while being initiated with a Buy at Needham and Guggenheim. 4. Ingersoll-Rand (IR) initiated with an Outperform at Cowen. 5. Ally Financial (ALLY) initiated with a Neutral at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/18
LEER
06/19/18
INITIATION
Target $18
LEER
Outperform
Iterum Therapeutics initiated with an Outperform at Leerink
Leerink analyst Ami Fadia initiated Iterum Therapeutics with an Outperform and $18 price target.
CUTR Cutera
$20.32

0.24 (1.20%)

10/05/18
SPHN
10/05/18
NO CHANGE
Target $40
SPHN
Overweight
Cutera price target lowered to $40 from $50 at Stephens
Stephens analyst Chris Cooley noted that Cutera's Q3 negative pre-announcement marked the third consecutive quarterly shortfall for the company and he lowered his price target on the stock to $40 in reaction to the news. While he believes the shares are likely to continue to underperform through the end of the calendar year, Cooley said he is inclined to take a longer-term focus and hold rather than sell while waiting for growth to accelerate in 2019. He maintains an Overweight rating on Cutera shares, which are down 16% to $24.94 in pre-market trading.
04/16/18
STFL
04/16/18
INITIATION
Target $55
STFL
Hold
Cutera initiated with a Hold at Stifel
Stifel analyst Jonathan Black initiated Cutera with a Hold and $55 price target.
10/10/18
SPHN
10/10/18
NO CHANGE
Target $40
SPHN
Overweight
Stephens says now time to step in on Cutera
Stephens analyst Chris Cooley said he remains confident Cutera can deliver upon its stated 2021 objectives despite 2018 not unfolding as originally forecast as he believes truSculpt ID offers the potential to more that double the company's current share of the body contouring market by 2021. The analyst, who also thinks Cutera's margins have reached a trough and may favorably inflect exiting this year, sees now as the time to step in and reiterates his Overweight rating and $40 price target on Cutera shares.
10/05/18
STFL
10/05/18
NO CHANGE
Target $29
STFL
Hold
Cutera price target lowered to $29 from $45 at Stifel
Stifel analyst Jonathan Block said that while he believes Cutera is putting the right long-term pieces in place, some initiatives may take time and he prefers to see how 2019 revenue growth plays out before he would become more constructive on the shares. The analyst, who noted that the company had previously cut its 2018 EPS view meaningfully on its Q2 earnings call prior to last night's negative pre-announcement regarding Q3, keeps a Hold rating on Cutera shares and lowered his price target to $29 from $45.
IBIO iBio
$0.78

0.045 (6.16%)

HRC Hill-Rom
$93.52

-0.9 (-0.95%)

10/15/18
LEHM
10/15/18
INITIATION
LEHM
Equal Weight
Hill-Rom initiated with an Equal Weight at Barclays
Barclays analyst Kristen Stewart initiated Hill-Rom with an Equal Weight rating and $95 price target.
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
07/17/18
KEYB
07/17/18
NO CHANGE
Target $115
KEYB
Overweight
Hill-Rom price target raised to $115 from $97 at KeyBanc
KeyBanc analyst Matthew Mishan raised his price target for Hill-Rom to $115 from $97 as he believes investors could grow increasingly confident in an improved long-term growth outlook. The analyst reiterates an Overweight rating on the shares.
04/04/18
GSCO
04/04/18
INITIATION
Target $85
GSCO
Neutral
Hill-Rom initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Issac Ro started Hill-Rom with a Neutral rating and $85 price target.
TRXC TransEnterix
$2.88

-0.2 (-6.49%)

06/28/18
BTIG
06/28/18
DOWNGRADE
BTIG
Neutral
TransEnterix downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded TransEnterix to Neutral citing the "rapid" rise in shares.
05/29/18
LTCO
05/29/18
DOWNGRADE
LTCO
Neutral
TransEnterix downgraded to Neutral from Buy at Ladenburg
05/29/18
05/29/18
DOWNGRADE
Target $4

Neutral
TransEnterix downgraded to Neutral with $4 price target at Ladenburg
As previously reported, Ladenburg analyst Jeffrey Cohen downgraded TransEnterix to Neutral from Buy citing valuation with the stock having rallied after the company received FDA approval for expanded indications that now mean the Senhance system is approved for the most commonly performed surgeries in more than 95% of hospitals nationally. Cohen raised his price target for TransEnterix to $4 from $3.50.
11/09/18
LTCO
11/09/18
UPGRADE
Target $4.5
LTCO
Buy
TransEnterix upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen upgraded TransEnterix to Buy while lowering his price target for the shares to $4.50 from $6.

TODAY'S FREE FLY STORIES

ALSN

Allison Transmission

$43.06

-0.96 (-2.18%)

15:30
08/23/19
08/23
15:30
08/23/19
15:30
Conference/Events
Allison Transmission management to meet with RBC Capital »

Meeting to be held In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

15:30
08/23/19
08/23
15:30
08/23/19
15:30
General news
Treasury Action: bond yields have inched up from intraday lows »

Treasury Action: bond…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:22
08/23/19
08/23
15:22
08/23/19
15:22
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) at…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/23/19
08/23
15:17
08/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/23/19
08/23
15:16
08/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$12.53

-0.24 (-1.88%)

15:15
08/23/19
08/23
15:15
08/23/19
15:15
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

15:12
08/23/19
08/23
15:12
08/23/19
15:12
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

At time of writing the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDOG

Datadog

$0.00

(0.00%)

15:11
08/23/19
08/23
15:11
08/23/19
15:11
Syndicate
Datadog files S-1 for IPO, seeks to list on Nasdaq with symbol 'DDOG' »

Datadog filed an S-1 with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$18.17

-0.87 (-4.57%)

15:05
08/23/19
08/23
15:05
08/23/19
15:05
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 20

    Sep

INCY

Incyte

$82.37

-3.2 (-3.74%)

, LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

14:58
08/23/19
08/23
14:58
08/23/19
14:58
Hot Stocks
Eli Lilly, Incyte announce baricitinib meets primary endpoint in Phase 3 trial »

Eli Lilly (LLY) and…

INCY

Incyte

$82.37

-3.2 (-3.74%)

LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

EPD

Enterprise Products

$28.35

-0.605 (-2.09%)

14:55
08/23/19
08/23
14:55
08/23/19
14:55
Options
Enterprise Products put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

, LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

14:54
08/23/19
08/23
14:54
08/23/19
14:54
On The Fly
Box Office Battle: 'Angel has Fallen' looking to swoop into top spot »

Welcome to "Box Office…

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

SNE

Sony

$53.87

-0.91 (-1.66%)

CMCSA

Comcast

$42.75

-1.01 (-2.31%)

CMCSK

Comcast

$0.00

(0.00%)

T

AT&T

$34.95

-0.44 (-1.24%)

CBS

CBS

$42.02

-1.43 (-3.29%)

DIS

Disney

$133.09

-2.98 (-2.19%)

VIA

Viacom

$27.31

-0.28 (-1.01%)

VIAB

Viacom

$25.01

-0.85 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 05

    Sep

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Oct

  • 27

    Oct

QSR

Restaurant Brands

$76.37

0.94 (1.25%)

14:45
08/23/19
08/23
14:45
08/23/19
14:45
Options
Restaurant Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
08/23/19
08/23
14:45
08/23/19
14:45
General news
Fed funds futures surge on the downdraft in stocks »

Fed funds futures surge…

OSW

OneSpaWorld

$15.84

-0.22 (-1.37%)

14:41
08/23/19
08/23
14:41
08/23/19
14:41
Conference/Events
OneSpaWorld management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

OPRX

OptimizeRx

$15.16

-0.39 (-2.51%)

14:38
08/23/19
08/23
14:38
08/23/19
14:38
Conference/Events
OptimizeRx management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 12

    Sep

APPN

Appian

$60.63

0.29 (0.48%)

14:37
08/23/19
08/23
14:37
08/23/19
14:37
Conference/Events
Appian management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 27

    Aug

ET

Energy Transfer LP

$13.35

-0.31 (-2.27%)

14:35
08/23/19
08/23
14:35
08/23/19
14:35
Options
Energy Transfer put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$17.04

0.05 (0.29%)

14:25
08/23/19
08/23
14:25
08/23/19
14:25
Options
Nektar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

14:20
08/23/19
08/23
14:20
08/23/19
14:20
General news
Treasury Action: yields remain sharply lower on a flight to safety »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/23/19
08/23
14:17
08/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

, DIS

Disney

$133.27

-2.8 (-2.06%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Periodicals
Sinclair CEO eyes more regional sports network acquisitions, WSJ reports »

Sinclair Broadcast (SBGI)…

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

DIS

Disney

$133.27

-2.8 (-2.06%)

T

AT&T

$34.97

-0.425 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Sep

  • 23

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$95.83

-3.315 (-3.34%)

14:15
08/23/19
08/23
14:15
08/23/19
14:15
Options
Diamondback Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 11

    Sep

14:10
08/23/19
08/23
14:10
08/23/19
14:10
General news
Action Economics Survey results: »

Action Economics Survey…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.